Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis: Comparison of on-demand esomeprazole with conventional omeprazole strategies

PharmacoEconomics

Volumn 20, Issue 4, 2002, Pages 267-277

  Wahlqvist, P ^a   Junghard, O ^a   Higgins, A ^b   Green, J ^c  

^a ASTRAZENECA R AND D   (Sweden)

^b ASTRAZENECA   (United Kingdom)

^c CITY GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; OMEPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; ESOPHAGITIS; EVALUATION; FOLLOW UP; GASTROESOPHAGEAL REFLUX; HEALTH CARE COST; HEARTBURN; HUMAN; LONG TERM CARE; NATIONAL HEALTH SERVICE; PRIORITY JOURNAL; PROBABILITY; RELAPSE; UNITED KINGDOM;

EID: 0036250865     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200220040-00005     Document Type: Article

References (46)

1. Dyspepsia: A dilemma for doctors?
2. Prevalence and clinical spectrum of gastroesophageal reflux: A population-based study in Olmsted County, Minnesota
3. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice
4. Gastro-oesophageal reflux disease in primary care in Europe: Clinical presentation and endosopic findings
5. Symptoms and endoscopic findings in the diagnosis of gastroesophageal reflux disease
6. The impact of gastroesophageal reflux disease on health-related quality of life
7. Symptoms of gastroesophageal reflux disease, perceived productivity, and health-related quality of life
8. Quality of life during acute and intermittent treatment of gastro-oesophageal reflux disease with omeprazole compared with ranitidine: Results from a multicentre clinical trial
9. The illness behavior of patients with gastroesophageal reflux disease with and without endoscopic esophagitis
10. Cost effectiveness of treatment for gastro-oesophageal reflux disease in clinical practice: A clinical database analysis
11. GERD in primary care. Comparison and development of European guidelines on gastroesophageal reflux disease
12. Medical treatment of gastro-oesophageal reflux disease
13. Pharmacological management of gastro-oesophageal reflux disease
14. The medical management of gastro-oesophageal reflux
15. Acid-reflux disorders
16. An evidence-based appraisal of reflux disease management - The Genval workshop report
17. Gastro-oesophageal reflux disease
18. Gastro-oesophageal reflux disease in primary care: An international study of different treatment strategies with omeprazole
19. A randomised comparison between omeprazole and open anti-reflux surgery in the management of chronic gastro-oesophageal reflux disease: Report on 5 year follow up
20. Long-term management of gastro-oesophageal reflux disease with omeprazole or open anti-reflux surgery: Results of a prospective, randomised clinical trial
21. Omeprazole is superior to ranitidine in curing and further managing patients with heartburn
22. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis-a placebo-controlled randomized trial
23. Maintenance treatment for gastro-oesophageal reflux disease: A placebo- controlled evaluation of 10 milligrams omeprazole once daily in general practice
24. Long-term prescribing of proton pump inhibitors in general practice
25. Management of GORD in the UK: Results of a survey
26. Esomeprazole 40 mg provides more effective acid control than standard doses of all other proton pump inhibitors
27. Esomeprazole 40mg and 20mg is efficacious in the long-term management of patients with endoscopy-negative GERD: A placebo-controlled trial of on-demand therapy for 6 months
28. Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: A controlled trial of 'on-demand' therapy for 6 months
29. Markov models in medical decision making: A practical guide
30. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis
31. Heartburn, oesophagitis and Barrett's oesophagus in self-medicating patients in general practice
32. Relevance of norm values as part of the documentation of quality of life instruments for use in upper gastrointestinal disease
33. The impact of functional gastrointestinal disorders on quality of life
34. Upper gastrointestinal symptoms in North America: Prevalence and relationship to healthcare utilization and quality of life
35. Gastroesophageal reflux: Therapy considerations after failure of low-dose, nonprescription H2RAs
36. Trends in the management of gastro-oesophageal reflux disease
37. Long-term management of gastroesophageal reflux disease
38. Assessment of patient satisfaction with a formulary switch from omeprazole to lansoprazole in gastroesophageal reflux disease maintenance therapy
39. Clinical and humanistic outcomes in patients with gastroesophageal reflux disease converted from omeprazole to lansoprazole
40. How satisfied are chronic heartburn sufferers with the results they get from prescription strength heartburn medication